benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate

We are benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate CAS:219835-31-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate
CAS.NO:219835-31-1
Synonyms:benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate
(R)-Benzyl (1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl)carbamate
(R)-N-Benzyl-2-(benzyloxycarbonylamino)-3-hydroxypropionamide
 
Physical and Chemical Properties:
Density 1.238
Melting Point 147-149 ºC
Molecular Formula C18H20N2O4
Molecular Weight 328.36200
 
Specification:
Appearance:White to off-white powder
Loss on drying:≤1.0%
Specific rotation:+4.4º~+5.1º(C=1g/100ml in MEOH)
Melting point:147-152ºC
Residue on ignition:≤0.1%
Heavy metals:≤20ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lacosamide(CAS:175481-36-4).

benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate


Related News: The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).164861-52-3 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.B,B'-2,8-Dibenzofurandiylbisboronic acid CAS:1222008-13-0 Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.3-Chlorobenzyl cyanide Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities.

Related Products
Product Name
4-Bromo-3-fluorobenzaldehyde View Details
(5-formylfuran-2-yl)boronic acid View Details
2,2,3-trifluoro-3-(trifluoromethyl)oxirane View Details
Myristoyl Pentapeptide-8 manufacturer methyl 4-chloropyridine-2-carboxylate,hydrochloride manufacturer 3-BROMO-5-FLUOROBENZALDEHYDE manufacturer 10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine manufacturer L-Histidine Monohydrochloride Monohydrate manufacturer